TECH - Bio-Techne Inc. Company Value to Earnings Growth Ratio

Brandmark of Bio-Techne Corporation (TECH)

Global laboratory reach and protein production have provided Bio-Techne Corporation (TECH) with financial autonomy, as confirmed by the relative undervaluation indicated by the PEG ratio. The value of 3.90 represents the latest metric reading, highlighting the efficiency of R&D investments in retaining top specialists. This has enabled the company to strengthen its patent portfolio, successfully competing in the medtech sector while maintaining high operational profitability.

Techne Corporation (TECH): PEG Multiple from 07/04/2022 to 11/10/2026

Metric breakdowns and analytics for Bio-Techne Corporation (TECH)

- price and consensus price forecast:
Market Chart Bio-Techne Corp|TECH - Consensus Target
- market capitalization statistics:
Market Value Techne Corporation|TECH - Enterprise Value
- book capitalization information:
Net Assets per Share Bio-Techne|TECH - Book Capitalization|Market Cap to Net Assets Ratio bio-techne.com|TECH - Cumulative Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Bio-Techne Corporation|TECH - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio bio-techne.com|TECH - Company Aggregate Debts|Debts to Book Value Techne Corporation|TECH - Company Long-Term Debts|Company Short-Term Indebtedness Bio-Techne|Interim Coverage Ratio bio-techne.com
- net income and valuation ratios data:
TECH - Net Profit|Future Profit Bio-Techne Corporation|TECH - P/E Multiple|Forward P/E Multiple Bio-Techne Inc.|TECH - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Techne Corporation|TECH - Operating profit before deduction of amortization|Earnings per share for the trailing year Bio-Techne|TECH - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months bio-techne.com|TECH - Earnings per share growth in current year|Net earnings per one share growth forecast for next year Bio-Techne Corporation
General company analysis:TECH - Bio-Techne Corp
Finished products of Bio-Techne

Effective asset selection is based on comparing market value with earnings growth, where a value below one signals that a company is undervalued relative to its expansion. This P/E growth potential metric measures the balance between price and development rates, which for Bio-Techne Corporation (TECH) is supported by strong pricing power derived from their proteins serving as the industry standard.

Competing companies

Growth-Adjusted Market Cap to Net Income Abbott Labs|Thermo Fisher Corp - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio GEHC (GE HealthCare Inc.)|Mettler-Toledo International - PEG Multiple|Growth-Adjusted Market Cap to Net Income waters.com WAT|BRKR: PEG Multiple|Price/Earnings to Growth Multiple Azenta Inc|Price/Earnings to Growth Multiple VREX|SMLR: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Butterfly Network, Inc. (BFLY)|Price/Earnings to Growth Multiple mesalabs.com MLAB|PEG Multiple QSI (Quantum-Si Incorporated)|Nano-X Imaging (NNOX) - Price to Earnings Adjusted for Growth Rate|Quanterix Corp - PEG Multiple|MASS (908 Devices Corporation) - Growth-Adjusted P/E Ratio|CV: PEG Multiple|MXCT - Growth-Adjusted Market Cap to Net Income|RPID (Rapid Micro Biosystems Inc.) - PEG Multiple|Price/Earnings to Growth Multiple Seer Inc (SEER)|PEG Multiple HYPR|PEG Multiple FONAR Corporation Inc (FONR)|Price/Earnings to Growth Ratio Daxor DXR|Spectral AI Inc. - Price/Earnings to Growth Ratio|VIVS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ACON (Aclarion Inc)|AKYA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Cesca Therapeutics (THMO)|Price/Earnings to Growth Ratio Talis Biomedical Corp.|TTOO - Price to Net Income Growth Ratio